Influence of anti-tumor necrosis factor (TNF) treatments on T cell cytokine production in patients with inflammatory joint diseases - comparison of etanercept and anti-TNF monoclonal antibodies. A double-blind, prospective, placebo-controlled study.
Year: 2025
Type: article
Abstract: cells; however, a decrease in the percentage of IL-17A-positive DN T cells was observed in the etanercept-treated group (mean±SEM: 0.82±0.55, 0.41±0.16, 0.13±0.07) in comparison to placebo (0.23±0.10, 0.32±0.12, 0.49±0.15), (p=0.014), and an opposite; however, insignificant trend was observed in the monoclonal antibody-receiving group (0.41±0.13, 0.53±0.17, 0.82±0.3), (p=0.056 vs. etanercept). In summary, we ascertain that treatment with TNF inhibitors does not affect Th1, Th2, or Th17 responses. Etanercept and monoclonal antibodies differ in their effect on IL-17A+DN T cells.
Source: PubMed
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4417184196
FWCI:
Cites:
Cited by:
Related to: